Stock Market Reviews

NKTX (Nkarta, Inc.) News

Get the latest news, insights, and market updates on NKTX (Nkarta, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• We Think Nkarta (NASDAQ:NKTX) Needs To Drive Business Growth Carefully
  Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
  Dec 4, 2025 - $NKTX
• Nkarta to Participate in Evercore Healthcare Conference
  SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkar
  Dec 2, 2025 - $NKTX
• Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights
  Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presente
  Nov 10, 2025 - $NKTX
• Nkarta to Participate in November Investor Conferences
  SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on
  Oct 30, 2025 - $NKTX
• Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting
  SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced it will be presenting a poster this Sunday in Chicago at the American College of Rheumatology (ACR) Convergence 2025 meeting. Nkarta will present clinical data showing that the company’s investigational therapy, NKX019, achieved robust pathogenic B-cell depletion
  Oct 22, 2025 - $NKTX
• Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight
  DelveInsight's Glomerulonephritis Market Insights report includes a comprehensive understanding of current treatment practices, glomerulonephritis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan).
  Oct 22, 2025 - $NKTX
• Nkarta to Participate in a September Investor Conference
  SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 9, 20258:30 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay w
  Sep 2, 2025 - $NKTX
• Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights
  Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the second quarter and year ended June 30
  Aug 12, 2025 - $NKTX
• Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series
  SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series. H.C Wainwright “HCW@Home with Nkarta, Inc.”July 30, 202511:00 a.m. ET – fireside chat Register for the webcast here. A simultaneous webcast of the event will also be available on the Investors section of Nkarta’s website, www.nkart
  Jul 23, 2025 - $NKTX
• Will Nkarta (NASDAQ:NKTX) Spend Its Cash Wisely?
  Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
  Jun 27, 2025 - $NKTX